| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:25 | Haleon drops supplier after AFP deforestation investigation | 4 | Alliance News | ||
| 07:24 | FDA expands Sanofi's Tzield use to children as young as 1 for type 1 diabetes delay | 4 | Seeking Alpha | ||
| 07:22 | FDA erweitert Zulassung für Sanofis Diabetes-Medikament Tzield auf Kleinkinder | 3 | Investing.com Deutsch | ||
| 07:18 | FDA approves Sanofi's Tzield for children as young as one year | 5 | Investing.com | ||
| 07:10 | Sanofi: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children | 114 | GlobeNewswire (Europe) | Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset... ► Artikel lesen | |
| 07:10 | Sanofi: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US | 111 | GlobeNewswire (Europe) | Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target... ► Artikel lesen | |
| 07:10 | Ipsen Pharma: Ojemda approved in the European Union as the first targeted therapy in relapsed or refractory pediatric low-grade glioma regardless of BRAF alteration | 115 | GlobeNewswire (Europe) | New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past five years have focused on pediatric diseases; Ojemda (tovorafenib) represents... ► Artikel lesen | |
| 07:09 | PRESSESPIEGEL/Unternehmen: MUNICH RE, GALERIA, CINVEN, ASTRAZENECA, ATMOS SPACE CARGO, OPENAI, REVOLUT | 151 | Dow Jones News | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
MUNICH RE - Zwei Jahre ist Nikolaus von Bomhard noch Chefkontrolleur... ► Artikel lesen | |
| 06:47 | China Resources Pharmaceutical Subsidiarys Category 3 Anti-rejection Generic Drug Approved for Production | 1 | AASTOCKS | ||
| 06:30 | Umsatz bei Bayer in Spanien um 4% rückläufig wegen Rückgang im Agrarsektor | 233 | fruchtportal.de | Bayer Spanien verzeichnete im Jahr 2025 im Vergleich zum Vorjahr einen Umsatzrückgang von 4 %, der bei 787 Mio. Euro lag. Besonders stark war der Rückgang in der Agrarsparte, die um 20 % sank. Das Unternehmen... ► Artikel lesen | |
| 05:42 | Achieve Life Sciences: Up To $354 Million Private Placement Funds Cytisinicline Development And Commercialization | 2 | pulse2.com | ||
| 05:18 | Vext Science Inc: Vext revises 2025 results release date to April 29 | 1 | Stockwatch | ||
| 05:17 | M Stanley Rates FOSUN PHARMA as Overweight With TP HKD32, Lifts Rev. Forecast | 3 | AASTOCKS | ||
| 04:42 | UCB: $1.15 Billion Neurona Therapeutics Acquisition To Advance Epilepsy Treatments | 1 | pulse2.com | ||
| 04:06 | GHIT Fund: Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi | 375 | PR Newswire | TOKYO, April 22, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million1) in five R&D... ► Artikel lesen | |
| 03:54 | Nektar prices $325M stock offering at $92 per share | 1 | Investing.com | ||
| 01:22 | F. Hoffmann-La Roche Ltd: Roche's fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS | 435 | GlobeNewswire (Europe) | Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis... ► Artikel lesen | |
| 01:18 | Pharmather Holdings Ltd: Pharmather hopes programs benefit from executive order | 2 | Stockwatch | ||
| 00:20 | PERCHERON THERAPEUTICS LIMITED: Notification regarding unquoted securities - PER | - | ASX | ||
| 00:17 | PERCHERON THERAPEUTICS LIMITED: Application for quotation of securities - PER | - | ASX |
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | Aktuelle Nachrichten | |||
|---|---|---|---|---|---|---|---|
| ELI LILLY | 18 | 125 | +0,35 % | Aktien unter Druck, aber mit deutlichem Potenzial - dynaCERT Inc., Eli Lilly, K+S, Novo Nordisk | Am Wochenende scheiterten die Verhandlungen zur Beendigung des Krieges zwischen den USA und dem Iran, doch schon Ende dieser Woche soll es bereits eine nächste Verhandlungsrunde geben. Das machte sich... ► Artikel lesen | ||
| MERCK & CO | 16 | 43 | +0,51 % | Merck & Co. (MRK): Die Bullen lauern an der 20-Tagelinie! | Konsolidierung auf hohem Niveau! Rückblick Die Aktie von Merck befindet sich in einer Korrekturphase innerhalb eines starken Aufwärtstrends. Der Markt "atmet durch", nachdem die Kurse schnell gestiegen... ► Artikel lesen | ||
| NOVO NORDISK | 14 | 40 | +0,34 % | Amazon shakes GLP-1 race as Eli Lilly, Novo Nordisk stocks fall | |||
| BAYER | 13 | 36 | 0,00 % | Ihre wichtigsten Termine: Alle Blicke auf: Bayer, Deutsche Telekom, Hewlett Packard Enterprise & Clariant | © Foto: Bernd von Jutrczenka - dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | ||
| ASTRAZENECA | 12 | 22 | +0,27 % | Astra Zeneca kritisiert geplante Kürzungen im Gesundheitssystem | Cambridge - Der britische Hersteller Astra Zeneca hat vor möglichen Folgen der Kürzungen im deutschen Gesundheitssystem gewarnt. Man könne ab dem kommenden Jahr keine neuen Arzneien aus der Forschung... ► Artikel lesen | ||
| ROCHE | 9 | 20 | -0,01 % | F. Hoffmann-La Roche Ltd: Roche's fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS | Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple sclerosis... ► Artikel lesen | ||
| SSY GROUP | 8 | - | - | SSY Group: Furosemide Approved in China as Active Pharmaceutical Ingredient for Marketed Formulations | |||
| PFIZER | 7 | 92 | +0,58 % | Astellas, Pfizer Say FDA Grants Priority Review To SBLA For PADCEV Plus Keytruda | TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) and Pfizer Inc. (PFE) on Monday said the U.S. Food and Drug Administration has granted Priority Review for a supplemental Biologics License Application... ► Artikel lesen | ||
| EISAI | 6 | 5 | +0,63 % | GHIT Fund: Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi | TOKYO, April 22, 2026 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.37 billion (USD 8.5 million1) in five R&D... ► Artikel lesen | ||
| SHANGHAI FOSUN PHARMACEUTICAL | 6 | 5 | +0,33 % | M Stanley Rates FOSUN PHARMA as Overweight With TP HKD32, Lifts Rev. Forecast |
| Unternehmen / Aktien | Aktueller Kurs | Ø Kursziel (Euro) | Potential (Euro) | kaufen | halten | verkaufen | |||
|---|---|---|---|---|---|---|---|---|---|
| ELI LILLY AND COMPANY | 772,90 | 968,78 | +25 % | 1 | - | - | |||
| SCHOTT PHARMA AG & CO KGAA | 15,420 | 18,70 | +21 % | 3 | 9 | - | |||
| MERCK KGAA | 117,50 | 140,40 | +19 % | 10 | 7 | - | |||
| SANOFI SA | 81,81 | 94,57 | +16 % | 9 | 15 | - | |||
| ASTRAZENECA PLC | 167,55 | 191,96 | +15 % | 25 | 1 | 6 | |||
| ROCHE HOLDING AG PS | 341,83 | 383,19 | +12 % | 11 | 17 | 4 | |||
| BAYER AG | 40,030 | 44,71 | +12 % | 25 | 10 | 1 | |||
| NOVO NORDISK A/S | 33,700 | 37,47 | +11 % | 11 | 31 | 2 | |||
| PFIZER INC | 23,425 | 24,61 | +5 % | 1 | 4 | - | |||
| NOVARTIS AG | 126,86 | 129,57 | +2 % | 5 | 11 | 3 | |||
| GSK PLC | 23,930 | 22,73 | -5 % | 5 | 9 | 15 | |||
| DOCMORRIS AG | 7,860 | 6,95 | -12 % | 4 | 8 | 5 | |||
| DERMAPHARM HOLDING SE | 45,900 | 34 | -26 % | - | 2 | - |